Get the Stockscreener App
7.64
2.30%
-0.18
After Hours:
7.74
0.10
+1.31%
Corbus Pharmaceuticals Holdings Inc stock is traded at $7.64, with a volume of 912.05K.
It is down -2.30% in the last 24 hours and down -22.20% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$7.82
Open:
$7.67
24h Volume:
912.05K
Relative Volume:
2.53
Market Cap:
$141.55M
Revenue:
$1.54M
Net Income/Loss:
$-78.54M
P/E Ratio:
-1.278
EPS:
-5.978
Net Cash Flow:
$-64.50M
1W Performance:
-33.62%
1M Performance:
-22.20%
6M Performance:
-33.80%
1Y Performance:
+5.67%
1-Day Range:
$7.48
$7.80
1-Week Range:
$7.48
$12.88
52-Week Range:
$6.72
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
7.64 | 144.89M | 1.54M | -78.54M | -64.50M | -5.978 |
VRTX
Vertex Pharmaceuticals Inc
|
447.97 | 110.97B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
621.52 | 65.81B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
838.49 | 51.03B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.29 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.63 | 32.53B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP) - Seeking Alpha
CRBP Maintained by Wedbush -- Price Target Lowered to $30 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study - Moomoo
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals stock falls on trial data release - Investing.com
CRB-701 data advances Corbus (NASDAQ: CRBP) OPSCC and cervical plans - Stock Titan
Corbus slips on trial data for cancer candidate (CRBP:NASDAQ) - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc Pre-2026 ASCO Conference Call Transcript - GuruFocus
CRBP: CRB-701 and CRB-913 delivered promising efficacy and safety in cancer and obesity studies - TradingView
Mizuho raises Corbus Pharmaceuticals stock price target to $44 on ASCO data confidence - Investing.com Canada
CRBP: CRB-701 demonstrates strong efficacy and safety in 2L OPSCC and cervical cancer, with registrational trials planned - TradingView
Corbus Pharmaceuticals reports updated CRB-701 phase 1/2 clinical data demonstrating robust activity in 2L oropharyngeal and cervical cancers - marketscreener.com
HPV-linked throat and cervical cancer drug shrinks tumors in early trial - Stock Titan
Corbus Pharmaceuticals teases key ASCO cancer data, late-summer obesity readout - MSN
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Raises Target Price to $44 - Moomoo
CRBP Maintained by Mizuho -- Price Target Raised to $44.00 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus (CRBP) Chief Business Officer receives RSUs and 192,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) CBO Nishant Saxena reports holding 3,500 shares - Stock Titan
Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho - Moomoo
Colliers facilitates 36,471 s/f lease renewal for Corbus Pharmaceuticals - NEREJ
Mizuho raises Corbus Pharmaceuticals stock price target on ASCO preview By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - Sahm
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout - Barchart.com
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxen - The National Law Review
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (CRBP) grants RSUs and stock options to director - Stock Titan
Corbus Pharmaceuticals (CRBP) director granted RSUs and 12,300 stock options - Stock Titan
Corbus Pharmaceuticals (CRBP) director receives RSUs and 12,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) director Anne Altmeyer receives RSU and stock option grants - Stock Titan
Equity grants increase Corbus (CRBP) director Ben Yong’s holdings - Stock Titan
Corbus (NASDAQ: CRBP) director receives RSU and stock option grants in equity package - Stock Titan
Corbus Pharmaceuticals (CRBP) director Brent Pfeiffenberger files initial Form 3 - Stock Titan
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Announces Pre-ASCO 2026 Data for CRB-701 in Oncology Trials - Minichart
Corbus Pharmaceuticals Appoints First Chief Business Officer - TipRanks
Corbus Pharmaceuticals announces the appointment of Nishant Saxena as chief business officer - marketscreener.com
Corbus appoints Brent Pfeiffenberger to board with equity awards - TradingView
Corbus Pharmaceuticals Holdings, Inc. announced that it will initiate a registration study of CRB-701 in second-line treatment for head and neck squamous cell carcinoma this summer. - Bitget
Corbus (NASDAQ: CRBP) hires Nishant Saxena as CBO, plans CRB-701 data call - Stock Titan
We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate - Sahm
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
3.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):